Screener
Nuvation Bio NUVB License — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Product revenue, net | $23,192 | $1,238 | $41,702 | $1,238 |
| Collaboration and license agreements revenue | 8,495 | 3,595 | 73,213 | 6,679 |
| Total revenue | 31,687 | 4,833 | 114,915 | 7,917 |
| Costs and expenses: | ||||
| Cost of sales | 911 | 172 | 1,286 | 172 |
| Cost of collaboration and license agreements revenue | 8,560 | 2,404 | 14,176 | 4,498 |
| Research and development | 30,661 | 27,362 | 65,708 | 51,963 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's license — revenue?
- Nuvation Bio (NUVB) reported license — revenue of $8.5M in Q2 2026.
- How has Nuvation Bio's license — revenue changed year-over-year?
- Nuvation Bio's license — revenue increased by 136.3% year-over-year, from $3.6M to $8.5M.
- What does license — revenue mean?
- This metric represents the total revenue recognized from licensing agreements, excluding any assessed taxes. It reflects the financial value generated from granting rights to intellectual property or therapeutic candidates to third-party partners. This is a key indicator of the company's ability to monetize its research and development pipeline through strategic partnerships.
Ask your AI about Nuvation Bio's license — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude